|
市場調査レポート
武田薬品工業：製薬企業分析レポート
Takeda Pipeline * Products * Performance * Potential
|
Abstract
Takeda is a research-based pharmaceutical company that has been engaged in the
pharmaceutical industry for over 220 years. This report provides a full review
of the company's activities together with sales forecasts for key products to
2010.
Takeda reported net sales of ¥935,213 million for the nine months ended 31st
December 2005, a 7% increase over the previous year's corresponding period,
supported by higher sales of in-house ethical drugs. The impact of foreign
exchange fluctuations increased revenues by ¥8 billion. Operating income was
up by 2% to ¥346,584 million, while net income rose by 14% to ¥281,142
million. Research and development expenditure increased by 36% to ¥116,056
million.
R&D Pipeline Overview
Takeda's pipeline is largely dominated by new indications/ formulations for
its core products Actos, Takepron, Blopress and Lupron. Encouragingly for the
company many of these developments are either awaiting approval or are in late
stage Phase III trials. Takeda has also highlighted three novel candidate
drugs as future growth drivers:
- Rozerem, an in-house developed melatonin MT1/MT2 agonist, was
launched in September 2005 and is in Phase III trials in the EU and Japan for
insomnia.
- Lubiprostone has been approved for chronic idiopathic constipation
in the US, and has been filed for approval in this indication in Japan.
- Dimesna, currently in Phase III trials in the US, has been
developed by BioNumerik Pharmaceuticals and licensed to Takeda for marketing.
Major Products Forecast to 2010
- Actos (Diabetes)
- Basen (Diabetes)
- Takepron (Gastrointestinal)
- Blopress (Cardiovascular)
- Lupron (Cardiovascular)
- Isovorin (Gastrointestinal)
- Benet (Musculoskeletal)
- Seltouch (Musculoskeletal)
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- R&D Expenditure
- Divisional Performance
- Sales By Business Area
- Operating Income By Business Area
- Total Assets By Business Area
- Geographic Performance
- Sales By Destination
- Sales By Origin
- Operating Income By Origin
- Ethical Sales (In-House) By Geographic Region
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Key R&D projects
- Discontinued R&D projects
- Discontinued Agreements
- Sales Forecast
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Metabolic - Products
- Major Launched Products
- Actos
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Generic Competition/Lawsuits
- Competitor Products
- Sales Forecast
- Clinical Trial Results
- Basen
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Metabolic - R&D
- Cetilistat
- SYR-322
- TAK-654
- Metabolic - Summary
- Growth Potential
- Limiting Factors
- Gastrointestinal - Products
- Major Launched Products
- Takepron/Prevacid/Zoton
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Licensees
- Competitor Products
- Generic Competition
- Sales Forecast
- Altat
- Gastrointestinal - R&D
- Lubiprostone/SPI-0211
- TAK-390MR
- Ilaprazole
- Gastrointestinal - Summary
- Cardiovascular - Products
- Major Launched Products
- Blopress
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Diabetic Retinopathy
- Clinical Trial Results - Heart Failure
- Adecut
- Calslot
- Cardiovascular - R&D
- Caldaret (MCC-135)
- TAK-475
- TAK-536
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Anticancer - Products
- Major Launched Products
- Isovorin
- Leuplin/Lupron/Enantone
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Lawsuits
- Patents
- Competitor Products
- Sales Forecast
- Canferon A
- Celeuk 40
- Morphine hydrochloride
- Anticancer - R&D
- Matuzumab/EMD 72000
- TAK-165
- Tavocept
- Anticancer - Summary
- Growth Potential
- Limiting Factors
- Musculoskeletal - Products
- Major Launched Products
- Benet
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Seltouch
- Enbrel
- Osten
- Musculoskeletal - R&D
- Musculoskeletal - Summary
- Anti-infective - Products
- Major Launched Products
- Pansporin
- Sales
- Key Markets/Indications/Launches
- Competitor Products
- Sales Forecast
- Firstcin
- Others
- Anti-infective - R&D
- R851
- TAK-187
- TAK-220
- TAK-242
- Anti-infective - Summary
- Central Nervous System - Products
- Rozerem
- Further Development
- Clinical Trial Results
- Central Nervous System - R&D
- Ruboxistaurin (LY333531)
- TAK-128
- TAK-147
- TAK-428
- Central Nervous System - Summary
- Other - Products
- Dasen
- Prostal
- Solfa
- TMR
- Uprima/Ixense
- Key Markets/Indications/Formulations
- Further Development
- Other - R&D
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- 3M Pharmaceuticals
- Abbott
- 7th March 2000
- 20th December 2005
- Affymax Inc
- Alizyme plc
- 8th August 2003
- 30th January 2004
- Andrx Corporation
- ASKA Pharmaceutical, KI Pharma
- 16th March 2006
- Cerexa Pharmaceuticals Inc
- 30th September 2003
- 19th October 2005
- Eli Lilly
- 25th August 1999
- 18th December 2003
- Evotec
- IL YANG Pharmaceutical Ltd
- Kissei Pharmaceutical Co Ltd
- 5th August 2002
- 11th May 2004
- Ligand Pharmaceuticals Inc
- Merck KGaA
- Mitsubishi Pharma Corporation
- Paradigm Therapeutics Ltd
- PPD Inc
- Pronova Biocare AS
- Santhera Pharmaceuticals AG
- 3rd August 2005
- 15th December 2005
- Schering AG
- Sucampo Pharmaceuticals Inc
- 1st November 2004
- 31st March 2005
- Teijin Limited
- Toray Industries Ltd
- Licensing
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
APPENDIX 6 - PRODUCT INDEX
|
